Impact of Pre-Existing and New-Onset Atrial Fibrillation on Outcomes After Transcatheter Aortic Valve Replacement

Overview

Journal JACC Cardiovasc Interv

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2019 Oct 21

PMID 31629743

Citations 36

Authors

Amgad Mentias

Marwan Saad

Saket Girotra

Milind Desai

Ayman Elbadawi

Alexandros Briasoulis

Paulino Alvarez

Musab Alqasrawi

Michael Giudici

Sidakpal Panaich

Phillip A Horwitz

Hani Jneid

Samir Kapadia

Mary Vaughan Sarrazin

Affiliations

Soon will be listed here.

Abstract

Objectives: This study sought to evaluate impact of new-onset and pre-existing atrial fibrillation (AF) on transcatheter aortic valve replacement (TAVR) long-term outcomes compared with patients without AF.

Background: Pre-existing and new-onset AF in patients undergoing TAVR are associated with poor outcomes.

Methods: The study identified 72,660 patients ≥65 years of age who underwent nonapical TAVR between 2014 and 2016 using Medicare inpatient claims. History of AF was defined by diagnoses on claims during the 3 years preceding the TAVR, and new-onset AF was defined as occurrence of AF during the TAVR admission or within 30 days after TAVR in a patient without prior history of AF. Outcomes included all-cause mortality, and readmission for bleeding, stroke, and heart failure (HF).

Results: Overall, 40.7% had pre-existing AF (n = 29,563) and 6.8% experienced new-onset AF (n = 2,948) after TAVR. Mean age was 81.3, 82.4, and 83.8 years in patients with no AF, pre-existing, and new-onset AF, respectively. Pre-existing AF patients had the highest burden of comorbidities. After follow-up of 73,732 person-years, mortality was higher with new-onset AF compared with pre-existing and no AF (29.7, 22.6, and 12.8 per 100 person-years, respectively; p < 0.001). After adjusting for patient characteristics and hospital TAVR volume, new-onset AF remained associated with higher mortality compared with no AF (adjusted hazard ratio: 2.068, 95% confidence interval [CI]: 1.92 to 2.20; p < 0.01) and pre-existing AF (adjusted hazard ratio: 1.35; 95% CI: 1.26 to 1.45; p < 0.01). In competing risk analysis, new-onset AF was associated with higher risk of bleeding (subdistribution hazard ratio [sHR]: 1.66; 95% CI: 1.48 to 1.86; p < 0.01), stroke (sHR: 1.92; 95% CI: 1.63 to 2.26; p < 0.01), and HF (sHR: 1.98; 95% CI: 1.81 to 2.16; p < 0.01) compared with pre-existing AF.

Conclusions: In patients undergoing TAVR, new-onset AF is associated with increased risk of mortality and bleeding, stroke, and HF hospitalizations compared with pre-existing AF or no AF.

Citing Articles

Associations between cardiac arrhythmias and cardiovascular disease incidence and all-cause mortality: the Kailuan study.

Yang X, Geng T, Peng Y, Cui L, Chen S, Wang G BMC Public Health. 2024; 24(1):3266.

PMID: 39587558 PMC: 11587752. DOI: 10.1186/s12889-024-20703-6.

Potential Diagnostic and Prognostic Values of Left Atrial Strain in Valvular Heart Disease.

Anwar A J Cardiovasc Echogr. 2024; 34(2):41-49.

PMID: 39086705 PMC: 11288298. DOI: 10.4103/jcecho.jcecho_9_24.

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation.

Pallante F, Costa F, Garcia Ruiz V, Vizzari G, Iannello P, Teresi L J Clin Med. 2024; 13(13).

PMID: 38999202 PMC: 11242616. DOI: 10.3390/jcm13133636.

Cerebrovascular events after transcatheter aortic valve implantation.

Reddy P, Merdler I, Ben-Dor I, Satler L, Rogers T, Waksman R EuroIntervention. 2024; 20(13):e793-e805.

PMID: 38949240 PMC: 11200663. DOI: 10.4244/EIJ-D-23-01087.

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers After Transcatheter Aortic Valve Replacement: A Meta-Analysis.

Bhat V, Kumar A, Kalra A JACC Adv. 2024; 3(5):100927.

PMID: 38939627 PMC: 11198320. DOI: 10.1016/j.jacadv.2024.100927.

References

Holmes Jr D, Brennan J, Rumsfeld J, Dai D, OBrien S, Vemulapalli S . Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015; 313(10):1019-28. DOI: 10.1001/jama.2015.1474. View

Popma J, Adams D, Reardon M, Yakubov S, Kleiman N, Heimansohn D . Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014; 63(19):1972-81. DOI: 10.1016/j.jacc.2014.02.556. View

Tarantini G, Mojoli M, Urena M, Vahanian A . Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J. 2016; 38(17):1285-1293. DOI: 10.1093/eurheartj/ehw456. View

Truong V, Chung E, Nagueh S, Kereiakes D, Schaaf J, Volz B . Effect of transcatheter aortic valve replacement on left atrial function. Echocardiography. 2018; 35(11):1713-1720. DOI: 10.1111/echo.14109. View

Barbash I, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M . Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2014; 85(3):468-77. DOI: 10.1002/ccd.25708. View

Stortecky S, Buellesfeld L, Wenaweser P, Heg D, Pilgrim T, Khattab A . Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013; 6(1):77-84. DOI: 10.1161/CIRCINTERVENTIONS.112.000124. View

Maan A, Heist E, Passeri J, Inglessis I, Baker J, Ptaszek L . Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol. 2014; 115(2):220-6. DOI: 10.1016/j.amjcard.2014.10.027. View

Tarantini G, Mojoli M, Windecker S, Wendler O, Lefevre T, Saia F . Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the SOURCE XT Prospective Multicenter Registry. JACC Cardiovasc Interv. 2016; 9(9):937-46. DOI: 10.1016/j.jcin.2016.01.037. View

Simon R, Makuch R . A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984; 3(1):35-44. DOI: 10.1002/sim.4780030106. View

10.

Vora A, Dai D, Matsuoka R, Harrison J, Hughes 4th G, Sherwood M . Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. JACC Cardiovasc Interv. 2018; 11(17):1746-1756. DOI: 10.1016/j.jcin.2018.05.042. View

11.

Schemper M, Henderson R . Predictive accuracy and explained variation in Cox regression. Biometrics. 2000; 56(1):249-55. DOI: 10.1111/j.0006-341x.2000.00249.x. View

12.

Elixhauser A, Steiner C, Harris D, Coffey R . Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8-27. DOI: 10.1097/00005650-199801000-00004. View

13.

Jensen P, Johnson K, Floyd J, Heckbert S, Carnahan R, Dublin S . A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:141-7. PMC: 3674852. DOI: 10.1002/pds.2317. View

14.

Leon M, Smith C, Mack M, Makkar R, Svensson L, Kodali S . Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016; 374(17):1609-20. DOI: 10.1056/NEJMoa1514616. View

15.

Mori M, Mahmood S, Geirsson A, Yun J, Cleman M, Forrest J . Trends in volume and risk profiles of patients undergoing isolated surgical and transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018; 93(6):E337-E342. DOI: 10.1002/ccd.27855. View

16.

Urena M, Hayek S, Cheema A, Serra V, Amat-Santos I, Nombela-Franco L . Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation. 2014; 131(5):469-77. DOI: 10.1161/CIRCULATIONAHA.114.011929. View

17.

Mack M, Leon M, Thourani V, Makkar R, Kodali S, Russo M . Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019; 380(18):1695-1705. DOI: 10.1056/NEJMoa1814052. View

18.

Grover F, Vemulapalli S, Carroll J, Edwards F, Mack M, Thourani V . 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2016; 69(10):1215-1230. DOI: 10.1016/j.jacc.2016.11.033. View

19.

Frendl G, Sodickson A, Chung M, Waldo A, Gersh B, Tisdale J . 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. J Thorac Cardiovasc Surg. 2014; 148(3):772-91. DOI: 10.1016/j.jtcvs.2014.06.037. View

20.

Kokotailo R, Hill M . Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005; 36(8):1776-81. DOI: 10.1161/01.STR.0000174293.17959.a1. View